研究单位：[1]Shanghai JMT-Bio Inc.[2]CSPC ZhongQi Pharmaceutical Technology Co., Ltd.[3]Affiliated Hospital of Hebei University,Baoding,China[4]Beijing Cancer Hospital,Beijing,China[5]Cancer Hospital Chinese Academy of Medical Sciences,Beijing,China[6]Chinese People's Liberation Army General Hospital,Beijing,China[7]Chongqing Cancer Hospital,Chongqing,China[8]Southwest Hospital of Army Medical University,Chongqing,China[9]Fujian Cancer Hospital,Fuzhou,China[10]Sun Yat-sen University Cancer Center,Guangzhou,China[11]The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,China[12]The First Affiliated Hospital of Sun Yat-Sen University,Guangzhou,China[13]Anhui Cancer Hospital,Hefei,China[14]Shandong Cancer Hospital,Jinan,China[15]Nanjing Chest Hospital,Nanjing,China[16]Fudan University Cancer Hospital,Shanghai,China[17]Shanghai Chest Hospital,Shanghai,China[18]Shanxi Provincial People's Hospital,Shanxi,China[19]The Fourth Hospital of Hebei Medical University,Shijia Zhuang,China[20]West China Hospital of Sichuan University,Sichuan,China[21]Shanxi Cancer Hospital,Taiyuan,China[22]Huazhong University of Science Tongji Hospital, Tongji Medical College,Wuhan,China[23]Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China[24]The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an,China[25]First Affiliated Hospital of Zhengzhou University,Zhengzhou,China[26]Henan Cancer Hospital,Zhengzhou,China
研究目的：
This study is a retrospective real-world study to evaluate the efficacy of Osimertinib for patients with advanced or metastatic EGFR 20exon insertion mutation (20ins) Non-Small Cell Lung Cancer.
